| Autor: |
Itzhaki Ben Zadok O; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (O.I.B.Z., P.S., A.N.).; Faculty of Medicine, Tel-Aviv University, Israel (O.I.B.Z.)., Simitsis P; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (O.I.B.Z., P.S., A.N.)., Jacobson C; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA (C.J., O.N., C.D., P.C., J.D.C., A.L., A.N.)., Nadeem O; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA (C.J., O.N., C.D., P.C., J.D.C., A.L., A.N.)., Frigault MJ; Division of Medical Oncology, Massachusetts General Hospital Cancer Center, Boston (M.J.F., N.R.)., Raje N; Division of Medical Oncology, Massachusetts General Hospital Cancer Center, Boston (M.J.F., N.R.)., Duffy C; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA (C.J., O.N., C.D., P.C., J.D.C., A.L., A.N.)., Costello P; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA (C.J., O.N., C.D., P.C., J.D.C., A.L., A.N.)., Dela Cruz J; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA (C.J., O.N., C.D., P.C., J.D.C., A.L., A.N.)., Looka A; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA (C.J., O.N., C.D., P.C., J.D.C., A.L., A.N.)., Nohria A; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (O.I.B.Z., P.S., A.N.).; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA (C.J., O.N., C.D., P.C., J.D.C., A.L., A.N.). |
| Abstrakt: |
Competing Interests: Dr Itzhaki Ben Zadok received consulting fees from Pfizer. Dr Nohria receives research support from Bristol Myers Squibb and consulting fees from Altathera Pharmaceuticals, AstraZeneca, Regeneron Pharmaceuticals and Takeda Oncology. Dr Jacobson receives research support from Kite/Gilead and Pfizer and consulting fees from Kite/Gilead, BMS/Celgene, Novartis, ImmPACT Bio, Miltenyi Bio, Abintus Bio, Caribou Bio, Morphosys, Abbvie, AstraZeneca, ADC Therapeutics, Ipsen, Synthekine, and Sana. Dr Nadeem receives research support from Takeda Oncology and Janssen Pharmaceuticals and consulting fees from Bristol Myers Squibb, Janssen, Takeda Oncology, Sanofi, GPCR Therapeutics, and Pfizer. Dr Raje received consulting fees from Janssen and Bristol Myers Squibb. Dr Frigault receives consulting fees from Kite, Novartis, Bristol Myers Squibb, and Johnson and Johnson/Legend. The remaining authors have nothing to disclose. |
